Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domain
The acute myeloid leukemia (AML) pipeline is experiencing significant growth, with over 200 companies developing more than 260 pipeline therapies. Notable companies include GlycoMimetics, Takeda Oncology, and TC Biopharm. The report emphasizes the advancement of novel therapies, such as Uproleselan and Pevonedistat, which are in various stages of development including Phase III trials. Additionally, recent designations like orphan drug status from the FDA for AML treatments highlight the urgency in addressing this prevalent disease. The comprehensive analysis covers the therapeutic landscape, including mechanisms of action and routes of administration.
- Over 200 companies are engaged in developing more than 260 AML therapies, indicating strong industry investment.
- Promising therapies in advanced stages include Uproleselan and Pevonedistat, which are pivotal for improving treatment outcomes.
- None.
The incidence of AML has gradually increased around the globe. Males and older people had a higher possibility to develop AML. Developed countries tended to have higher age-standardized incidence rates and death rates than developing regions. Novel therapies for AML, including refinements of conventional cytotoxic chemotherapies, genetic and epigenetic targeted drugs, as well as immunotherapies, have significantly improved patient outcomes in recent years.
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
- DelveInsight's acute myeloid leukemia pipeline report depicts a robust space with 200+ active players working to develop 260+ pipeline therapies for acute myeloid leukemia treatment.
- Key acute myeloid leukemia companies such as GlycoMimetics,
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. , Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene,TC Biopharm , PersonGen BioTherapeutics,Oncoceutics ,Janssen Research & Development, LLC , Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others are evaluating new acute myeloid leukemia drugs to improve the treatment landscape. - Promising acute myeloid leukemia pipeline therapies in various stages of development include Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
- In
January 2023 ,Innate Pharma SA announced the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. - In
January 2023 , the FDA granted JBI-802 orphan drug designation for patients diagnosed with small cell lung cancer (SCLC) and acute myeloid leukemia (AML), according to a press release from Jubilant Therapeutics. - In
January 2022 ,Astex Pharmaceuticals, Inc. announced that theEuropean Commission (EC) had granted orphan-drug designation (ODD) to the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).
Request a sample and discover the recent advances in acute myeloid leukemia drug treatment @ Acute Myeloid Leukemia Pipeline Report
The acute myeloid leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acute myeloid leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acute myeloid leukemia clinical trial landscape.
Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is the most common type of leukemia in adults, accounting for roughly
Chemotherapy is the primary treatment for most AML types, sometimes in conjunction with a targeted therapy drug. A stem cell transplant could follow this. Other drugs (aside from standard chemotherapy drugs) may be used to treat people with acute promyelocytic leukemia (APL).
Find out more about drugs for acute myeloid leukemia @ New Acute Myeloid Leukemia Drugs
A snapshot of the Acute Myeloid Leukemia Pipeline Drugs mentioned in the report:
Drugs | Company | Phase | MoA | RoA |
Omidubicel | Gamida Cell | Registered | Cell replacements | Intravenous |
Uproleselan | GlycoMimetics | Phase III | E-selectin inhibitors | Intravenous |
Pevonedistat | Takeda Oncology | Phase III | NEDD 8 activating enzyme inhibitors | Intravenous |
SKLB1028 | Phase III | Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors | Oral | |
BPX-501 | Bellicum Pharmaceuticals | Phase II | Immunologic cytotoxicity; T lymphocyte replacements | Intravenous |
ALT 803 | ImmunityBio | Phase II | Interleukin-15 receptor agonists | Intravenous |
Learn more about the emerging acute myeloid leukemia pipeline therapies @ Acute Myeloid Leukemia Clinical Trials
Acute Myeloid Leukemia Therapeutics Assessment
The acute myeloid leukemia pipeline report proffers an integral view of acute myeloid leukemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Acute Myeloid Leukemia Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous
- Therapeutics Assessment By Molecule Type: Small molecule, Cell therapy, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Cell replacements, E-selectin inhibitors, Interleukin-15 receptor agonists, Immunologic cytotoxicity, T lymphocyte replacements, Bcr-abl tyrosine kinase inhibitors, Epidermal growth factor receptor antagonists, Fms-like tyrosine kinase 3 inhibitors, Lyn protein-tyrosine kinase inhibitors, NEDD 8 activating enzyme inhibitors
- Key Acute Myeloid Leukemia Companies: GlycoMimetics,
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. , Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene,TC Biopharm , PersonGen BioTherapeutics,Oncoceutics ,Janssen Research & Development, LLC , Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others. - Key Acute Myeloid Leukemia Pipeline Therapies: Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
Dive deep into rich insights for new drugs for acute myeloid leukemia treatment; visit @ Acute Myeloid Leukemia Medications
Table of Contents
1. | Acute Myeloid Leukemia Pipeline Report Introduction |
2. | Acute Myeloid Leukemia Pipeline Report Executive Summary |
3. | Acute Myeloid Leukemia Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | Acute Myeloid Leukemia Clinical Trial Therapeutics |
6. | Acute Myeloid Leukemia Pipeline: Late Stage Products (Pre-registration) |
7. | Acute Myeloid Leukemia Pipeline: Late Stage Products (Phase III) |
8. | Acute Myeloid Leukemia Pipeline: Mid Stage Products (Phase II) |
9. | Acute Myeloid Leukemia Pipeline: Early Stage Products (Phase I) |
10. | Acute Myeloid Leukemia Pipeline Therapeutics Assessment |
11. | Inactive Products in the Acute Myeloid Leukemia Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the Acute Myeloid Leukemia Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the acute myeloid leukemia pipeline therapeutics, reach out @ Acute Myeloid Leukemia Drug Treatment
Related Reports
Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio,
Relapsed/Refractory Acute Myeloid Leukemia Epidemiology
Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted relapsed/refractory acute myeloid leukemia epidemiology in the 7MM.
Acute Lymphocytic Leukemia Pipeline
Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.
Chronic Lymphocytic Leukemia Pipeline
Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology,
Chronic Myeloid Leukemia Pipeline
Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell
Related Healthcare Blogs
Related Cases Studies
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/acute-myeloid-leukemia-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-200-companies-working-in-the-domain-301733237.html
SOURCE
FAQ
What is the current status of the AML pipeline as per the latest report?
What are some notable companies working on AML therapies?
What types of therapies are being developed for AML?
What recent regulatory designations have been given for AML therapies?
How does the AML pipeline impact TC Biopharm's stock performance?
